Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)
Key facts
- Who runs it
- Stanford University
- Where
- Stanford, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 150 people, planned
- Started
- 24 Feb 2024
- Expected to end
- Nov 2028
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Ketamine
- Naltrexone Pill
- Placebo pill
- Record updated
- 24 April 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Ages 18-65
- Meet the criteria for OCD diagnosis
- Failed at least 1 prior trial of standard first-line OCD treatment
- Agree to the following lifestyle modifications: comply with requirements for fasting prior to the Experimental Session, not enroll in any other interventional clinical trials during the duration of the study, and commit to medication study procedures
- Able to provide informed consent
- Ages 18-65
- Able to provide informed consent
Who cannot take part
- prior naltrexone or ketamine use/exposure
- current or past use of psychotropic medication
- Any current or past medical/psychiatric condition that makes participation unsafe in the opinion of the investigator or study physician
- Pregnant or nursing, or able to become pregnant and are not practicing an effective means of birth control
- the presence of metal in the body that is contraindicated for MRI scans; Eligibility Criteria for Healthy Volunteers:
- pregnant or nursing females
- the presence of metal in the body that is contraindicated for MRI scans
Other criteria
- Eligibility Criteria for Participants with OCD:
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
- Department of Psychiatry & Behavioral SciencesStanford, United StatesContact: OCD ResearchTaking people
About the trial
What the trial wants to find out
The purpose of this study is to understand how ketamine works in the brain to bring about a reduction in OCD symptoms.
The 3 groups in the trial
- Ketamine + NaltrexoneTreatment being tested
OCD patients in this arm will receive 0.5mg/kg of ketamine - one single infusion. fMRI will be acquired before, during, and after infusion. Oral naltrexone 50 mg will be administered before the infusion.
Treatment: Ketamine and Naltrexone Pill
- Ketamine + PlaceboPlacebo, for comparison
OCD patients in this arm will receive 0.5mg/kg of ketamine - one single infusion. fMRI will be acquired before, during, and after infusion. An oral inactive placebo will be administered before the infusion.
Treatment: Ketamine and Placebo pill
- Healthy VolunteersNo study treatment, for comparison
Healthy volunteers will have one fMRI scan visit.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Fit questions
- Built from NCT05940324, who can take part
- Record updated
- 24 April 2026